EP1917277A4 - Killing human lymphoma and leukemia cancer cells and tcr-activated normal human cells by dopamine d1r agonists - Google Patents

Killing human lymphoma and leukemia cancer cells and tcr-activated normal human cells by dopamine d1r agonists

Info

Publication number
EP1917277A4
EP1917277A4 EP06800733A EP06800733A EP1917277A4 EP 1917277 A4 EP1917277 A4 EP 1917277A4 EP 06800733 A EP06800733 A EP 06800733A EP 06800733 A EP06800733 A EP 06800733A EP 1917277 A4 EP1917277 A4 EP 1917277A4
Authority
EP
European Patent Office
Prior art keywords
cells
tcr
dopamine
agonists
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06800733A
Other languages
German (de)
French (fr)
Other versions
EP1917277A2 (en
Inventor
Mia Levite
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LEVITE, MIA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US2006/030360 external-priority patent/WO2007019266A2/en
Publication of EP1917277A2 publication Critical patent/EP1917277A2/en
Publication of EP1917277A4 publication Critical patent/EP1917277A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP06800733A 2005-08-03 2006-08-03 Killing human lymphoma and leukemia cancer cells and tcr-activated normal human cells by dopamine d1r agonists Withdrawn EP1917277A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70472905P 2005-08-03 2005-08-03
PCT/US2006/030360 WO2007019266A2 (en) 2005-08-03 2006-08-03 Killing human lymphoma and leukemia cancer cells and tcr-activated normal human cells by dopamine d1r agonists

Publications (2)

Publication Number Publication Date
EP1917277A2 EP1917277A2 (en) 2008-05-07
EP1917277A4 true EP1917277A4 (en) 2009-08-05

Family

ID=37727642

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06800733A Withdrawn EP1917277A4 (en) 2005-08-03 2006-08-03 Killing human lymphoma and leukemia cancer cells and tcr-activated normal human cells by dopamine d1r agonists

Country Status (2)

Country Link
EP (1) EP1917277A4 (en)
WO (1) WO2007019267A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428550B2 (en) 2012-01-18 2016-08-30 Governing Council Of The University Of Toronto Peptides and methods and uses thereof for preventing retinal disorders
EP2708235A1 (en) 2012-09-17 2014-03-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Peptide antagonists of the vasopressin-2 receptor
WO2019145956A1 (en) * 2018-01-25 2019-08-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods for improved immunotherapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103262A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells
US20050054652A1 (en) * 2002-07-29 2005-03-10 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020068704A1 (en) * 1999-04-05 2002-06-06 Ziegler Randy H. Compositions and methods for treatment of diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054652A1 (en) * 2002-07-29 2005-03-10 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
WO2004103262A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ACQUAS E ET AL: "The potent and selective dopamine D1 receptor agonist A-77636 increases cortical and hippocampal acetylcholine release in the rat", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER BV, NL, vol. 260, no. 1, 21 July 1994 (1994-07-21), pages 85 - 87, XP023749962, ISSN: 0014-2999, [retrieved on 19940721] *
DEVOINO L V ET AL: "Changes in the immune reaction of animals under conditions of drug-induced activation and blockade of D1 dopamine receptors", EXPERIMENTAL AND CLINICAL PHARMACOLOGY - EKSPERIMENTAL'NAA IKLINICESKAA FARMACOLOGIA, MOSCOW, vol. 67, no. 3, 1 May 2004 (2004-05-01), pages 48 - 50, XP009118367, ISSN: 0869-2092 *
JOHNSON D E ET AL: "The growth inhibitory properties of a dopamine agonist (SKF 38393) on MCF-7 cells", ANTI-CANCER DRUGS, RAPID COMMUNICATIONS, OXFORD, vol. 6, no. 3, 1 January 1995 (1995-01-01), pages 471 - 474, XP009118427, ISSN: 0959-4973 *
LIANG Y ET AL: "Bromocriptine/SKF38393 ameliorates islet dysfunction in the diabetic (db/db) mouse", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHAUSER VERLAG, HEIDELBERG, DE, vol. 54, no. 7, 1 July 1998 (1998-07-01), pages 703 - 711, XP009118426, ISSN: 1420-682X *
MATHUR VANDANA S: "The role of the DA1 receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients", REVIEWS IN CARDIOVASCULAR MEDICINE, vol. 4, no. Suppl1, 2003, pages S35 - S40, XP009118378 *
MURPHY MICHAEL B ET AL: "Fenoldopam: A selective peripheral dopamine-receptor agonist for the treatment of severe hypertension", NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US, vol. 345, no. 21, 22 November 2001 (2001-11-22), pages 1548 - 1557, XP009118469, ISSN: 0028-4793 *

Also Published As

Publication number Publication date
WO2007019267A1 (en) 2007-02-15
EP1917277A2 (en) 2008-05-07

Similar Documents

Publication Publication Date Title
IL184324A0 (en) Pyy agonists and uses thereof
EP1968582A4 (en) Treatment for cutaneous t cell lymphoma
SI1937244T1 (en) Treatment of cancer with specific rxr agonists
TWI372494B (en) Conductive contacts holder and conductive contacts unit
EP1909674A4 (en) Electrosurgical device and methods
IL177004A0 (en) Piperidinylcarbonyl- pyrrolidines and their use as melanocortin agonists
EP1863558A4 (en) Electrosurgical cannula
PL2041254T3 (en) Broad spectrum and skin friendly disinfecting composition
IL211089A0 (en) Compositions and methods for cell killing
EP1811936A4 (en) Thin protective underwear
GB201103239D0 (en) Thermotherapy device
AU311662S (en) Planter's knife
GB0519254D0 (en) Silver alloy
EP1977248A4 (en) Human zip1, zinc and citrate for prostate cancer screening
EP1944137A4 (en) Agent feeding device
EP1917277A4 (en) Killing human lymphoma and leukemia cancer cells and tcr-activated normal human cells by dopamine d1r agonists
GB0503509D0 (en) An improved delivery agent
IL200756A0 (en) Modified hydroxypolymer conjugates with killing effect on tumor cells
IL189160A0 (en) Killing human lymphoma and leukemia cancer cells and tcr-activated normal human cells by dopamine d1r agonists
GB0513860D0 (en) Silver alloy
ZA200605597B (en) Compositions for use with skin
GB0706658D0 (en) Breast cancer methods, medicaments and agents
GB0718365D0 (en) Straw holder
TWM291701U (en) Particle bait
AU2005907243A0 (en) Berley buddy fishing device

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071003

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LEVITE, MIA

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEVITE, MIA

A4 Supplementary search report drawn up and despatched

Effective date: 20090708

17Q First examination report despatched

Effective date: 20091016

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100302